<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01910077</url>
  </required_header>
  <id_info>
    <org_study_id>Tacrobell_BE-1301</org_study_id>
    <nct_id>NCT01910077</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Tacrobell Capsule 1mg to Prograf Capsule 1mg</brief_title>
  <official_title>An Open Label, Randomized, Single Dose, Crossover Pivotal Bioequivalence Study of Tacrobell Capsule 1mg Versus Prograf Capsule 1mg in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate bioequivalence between tacrobell capsule 1mg and
      prograf capsule 1mg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be an open label, randomized, single dose, 2-treatment, 2-period crossover study in
      healthy volunteers.Study treatments will be administered under fasting conditions.

      Blood samples for the analysis of tacrolimus in blood will be obtained as follows:
      Predose(immediately prior to dosing), and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6,
      8, 12, 24, 48, 72 and 96 hours postdose.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUClast</measure>
    <time_frame>At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdese</time_frame>
    <description>AUClast: Area under the blood concentration-time profile from time zero to the time of the last quantifiable concentration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdese</time_frame>
    <description>Cmax: Maximum blood concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUCinf</measure>
    <time_frame>At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdose</time_frame>
    <description>ACUinf: Area under the blood concentration-time profile from time zero extrapolated to infinite time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdose</time_frame>
    <description>Tmax: Time for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdose</time_frame>
    <description>T1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F</measure>
    <time_frame>At pre-dose (immediately prior to dosing) and 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 12, 24, 48, 72 and 96 hours postdose</time_frame>
    <description>CL/F: Apparent Clearance</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Tacrobell capsule 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus 1mg / 1 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prograf capsule 1mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus 1mg / 1 capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrobell capsule 1mg</intervention_name>
    <description>1 capsule, oral, over the period I&amp;II(crossover)</description>
    <arm_group_label>Tacrobell capsule 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prograf capsule 1mg</intervention_name>
    <description>1 capsule, oral, over the period I&amp;II(crossover)</description>
    <arm_group_label>Prograf capsule 1mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed the informed consent from prior to screening test

          -  Between 19 years and 55 years in healthy male subject

          -  Have not any congenital or chronic disease and medical symptoms

          -  Body mass index(BMI) of 18 to 30 and a total body weight â‰¥ 55kg

          -  Appropriate subject for the study judging from investigator

        Exclusion Criteria:

          -  Evidence or history of clinically significant hepatic, renal, neurologic, immune
             system, respiratory system, endocrine

          -  Any condition possibly affecting drug absorption (e.g. gastrectomy)

          -  Subject with hypersensitivity to tacrolimus or any excipient

          -  Administration of cyclosporin or bosentan

          -  Administration of potassium-sparing diuretics

          -  Subject with hereditary diseases of galactose intolerance, Lapp lactase deficiency or
             glucose-galactose malabsorption

          -  SBP&lt;90 mmHg or DBP&lt;50 mmHg, SBP&gt;150 mmHg or DBP&gt;100 mmHg at least 3 minutes of rest

          -  A positive HBsAg, HCV Ab, HIV Ab, RPR

          -  AST, ALT &gt; 1.5*upper limit of normal range at the screening test

          -  Subject with a history of drug abuse or a positive reaction for drug abuse at the
             screening test

          -  Taking ETC medicine including oriental medicine within 14days before the first
             hospitalization or taking OTC medicine, vitamin within 7days

          -  Use of any drugs known to significantly induce or inhibit drug-metabolizing enzymes
             within 30 days prior to initiation test

          -  Participating in a bioequivalence study or other clinical study within 3 month
             preceding the first hospitalization

          -  Blood donation or more within 2 month or component blood donation within 1 month prior
             to the first hospitalization

          -  Continued to be drinking(alcohol&gt; 21 units/week, 1 unit=10g of pure alcohol) or during
             clinical trials can not be drunk

          -  Severe heavy smoker(cigarette&gt; 10 cigarettes/day) during 3 months or can not be
             smoking during the clinical study

          -  Continued to be taking caffeine or can not be taken caffeine

          -  Continued to be taking grapefruit or can not be taken grapefruit

          -  Not use of contraception during the clinical study

          -  An impossible one who participates in the clinical trial by investigator's decision
             including for reason of laboratory test result
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyeong Ki Lee, MD, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul national university hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2013</study_first_submitted>
  <study_first_submitted_qc>July 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 29, 2013</study_first_posted>
  <last_update_submitted>July 21, 2014</last_update_submitted>
  <last_update_submitted_qc>July 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tacrolimus</keyword>
  <keyword>tacrobell capsule</keyword>
  <keyword>prograf capsule</keyword>
  <keyword>bioequivalence</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

